Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | TGM1 | P22735 | 1/20 | 0.41 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | LCAT | P04180 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14587774 | 0.84 | HSD11B1 (0.48) | HSD11B1KMT2AMALT1TRPV1F13A1 | |
| SCHEMBL30778167 | 0.82 | HSD11B1 (0.47) | HSD11B1KMT2AMALT1TRPV1F13A1 | |
| SCHEMBL4769377 | 0.82 | HSD11B1 (0.47) | HSD11B1KMT2AMALT1TRPV1DRD4 | |
| Hydrochloric Acid SCHEMBL4422336 | 0.81 | HSD11B1 (0.46) | HSD11B1KMT2AMALT1TRPV1DRD4 | |
| SCHEMBL17206944 | 0.81 | HSD11B1 (0.50) | HSD11B1KMT2AMALT1TRPV1PDE10A | |
| SCHEMBL3552058 | 0.81 | KMT2A (0.61) | HSD11B1KMT2AMALT1TRPV1PDE10A | |
| SCHEMBL2804196 | 0.80 | HSD11B1 (0.49) | HSD11B1KMT2AMALT1TRPV1 | |
| SCHEMBL3436628 | 0.80 | HSD11B1 (0.49) | HSD11B1KMT2AMALT1TRPV1DRD4 | |
| SCHEMBL3436511 | 0.80 | SMO (0.53) | HSD11B1KMT2AMALT1TRPV1DRD4 | |
| SCHEMBL24126285 | 0.77 | HSD11B1 (0.47) | HSD11B1KMT2AMALT1TRPV1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | claimed |
| US-7056937-B2 | Sulfonylquinoxalone derivatives as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | claimed |
| US-20040147519-A1 | Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | claimed |
| EP-1877401-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | Elan Pharmaceuticals Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006113140-A2 | NOVEL COMPOUNDS USEFUL FOR BRADYKININ B1 RECEPTOR ANTAGONISM | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| US-7056937-B2 | Sulfonylquinoxalone derivatives as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040147519-A1 | Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists | ELAN PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147519-A1 | Sulfonylquinoxalone acetamide derivatives as bradykinin antagonists | BDKRB2, BDKRB1, HRH2 | HSD11B1 3842/4885KMT2A 1951/4885MALT1 4839/4885 |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | HSD11B1 1893/4885KMT2A 4091/4885MALT1 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.